# OnCo record met-amplification-readout (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/met-amplification-readout/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "met-amplification-readout" ;
  schema:name "MET amplification (gene copy number)"@en ;
  schema:alternateName "MET amplification"@en, "MET amp"@en, "MET copy number gain"@en, "MET/CEP7 ratio"@en, "high-level MET amplification"@en, "MET GCN >= 10"@en ;
  schema:description "MET amplification means extra copies of the MET gene, either as a primary driver in a few lung cancers or as the escape route after EGFR inhibitors. No label yet selects on it; trials define it by FISH ratio or copy number."@en ;
  schema:url <https://onco.cc/biomarkers/met-amplification-readout/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03778229> ;
  onco:tag "biomarker", "met", "no-approval" ;
  onco:related <https://onco.cc/biomarkers/met-ex14/>, <https://onco.cc/biomarkers/met-overexpression/>, <https://onco.cc/biomarkers/egfr-t790m/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/gastric/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/telisotuzumab-vedotin/> ;
  onco:terms <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/fish/> .